🧬 New report: Mutant p53 & anti-cancer therapy response
Highlights:
- TP53 loss links mTOR activation and immune-cold MSS colorectal cancer
- TP53 mutations associate with improved PFS with cetuximab+pembrolizumab in CRC
@biomednews.bsky.social
#p53 #CancerResearch
biomed.news/bims-p53act/...